4World Health Organization. Companion handbook to the WHO guidelines for theprogrammatic management of drug- resistant tuberculosis. Geneva: World Health Organization, 2014.
5Nix DE, Adam RD, Auclair B, et al. Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis, 2004, 84(6): 365 -373.
6Moore VJ. A review of side-effects experienced by patients taking clofazimine. Lepr Rev, 1983, 54(4): 327-335.
7Dey T, Brigden G, Cox H, et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic re- view and meta-analysis. J Antimicrob Chemother, 2013, 68 (2) : 284-293.
8Diacon AH, Pyre A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med, 2009, 360(23): 2397 -2405.
9Andries K, Verhasseh P, Guillement J, et al. Adiarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005,307 (5707) : 223-227.
10WHO Guidelines Approved by the Guidelines Review Com- mmittee. The use of bedaquiline in the treatment of multidrug- resistant tuberculosis-Interim policy guidance. Geneva: World Health Organization, 2013.
